Dr. Maloney Discusses CAR T-Cell Therapy in Solid Tumors
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using CAR T-cell therapy in solid tumors.
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using chimeric antigen receptor (CAR) T-cell therapy in solid tumors.
Currently, the 2 approved indications for CAR T-cell therapy are in hematologic malignancies. In solid malignancies, CAR T cells have not been effective to date, says Maloney.
Maloney says that it is likely that CAR T cells will have to be combined with other agents to have an effect in solid tumors.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
